Early Investigator Research Award – Funding Level 1 – HT942526PRPEIRA
- Letters of Intent due 23 October 2026
- Up to USD$300,000 over 2 years
- Supports Parkinson’s disease research opportunities for investigators in the early stages of their careers.
- The PI must exhibit strong potential for and commitment to pursuing a career at the forefront of Parkinson’s disease research; however, they need not have previous Parkinson’s disease research experience.
- Early career investigators at the postdoctoral/clinical fellow level
- must include at least 1 experienced Parkinson’s disease research as a mentor
- preliminary data encouraged but not required
- clinical trials not allowed
- must address at least one of the focus areas
- Apply here
- Document – Program Announcement – HT942526PRPEIRA_GG
Early Investigator Research Award – Funding Level 2 – HT942526PRPEIRA
- Letters of Intent due 23 October 2026
- Up to USD$1M over 2 years
- Supports Parkinson’s disease research opportunities for investigators in the early stages of their careers (within 10 years of advanced degree or residency training or equivalent)
- The PI must exhibit strong potential for and commitment to pursuing a career at the forefront of Parkinson’s disease research; however, they need not have previous Parkinson’s disease research experience.
- early career, independent investigators
- mentor is not required
- preliminary data required
- clinical trials not allowed
- must address at least one of the focus areas
- Apply here
- Document – Program Announcement – HT942526PRPEIRA_GG
Investigator-Initiated Research Award – HT94256PRPIIRA
- Pre-applications due 23 October 2026
- Up to USD$2M over 3 years
- Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research.
- Supports basic science through clinical research studies.
- preliminary data required
- clinical trials allowed
- must address at least one of the focus areas
- Apply here
- Document – Program Announcement – HT942526PRPIIRA_GG
Focus Areas
- Understanding how Parkinson’s disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson’s disease
- Development and characterization of in vitro model systems that approximate in vivo cellular and system complexity
- Biological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for Parkinson’s disease. Applications can utilize laboratory models through to human participants
- Interventions that address unmet medical needs of Parkinson’s disease that include both clinical and preclinical models
